Index

ABPA, see Allergic bronchopulmonary aspergillosis
ACE inhibitors, see Angiotensin-converting enzyme inhibitors
Acrodermatitis enteropathica, atopic dermatitis differential diagnosis, 237
Acute otitis media, see Otitis media
AD, see Atopic dermatitis
ADA, see Adenosine deaminase
Adenosine deaminase (ADA), deficiency, 463
Adrenal insufficiency, corticosteroid risks, 394, 397
Adult asthma
allergic asthma
allergens, 110, 111
anaphylaxis mediators, 110, 111
diagnosis, 111, 112
mast cells, 109, 110
overview, 108, 109
pathological changes, 110, 112
allergic bronchopulmonary aspergillosis, 112, 113
clinical features
exercise-induced asthma, 127, 128
physical findings, 125, 126
severity classification, 126, 127
symptoms, 124, 125
differential diagnosis, 119, 120
drug induction, 115, 116
epidemiology, 107
exacerbating conditions
gastroesophageal reflux disease, 118
pregnancy, 119
sinusitis, 117, 118
idiopathic asthma, 117
infection, 114
management
allergen avoidance, 130, 131
allergen immunotherapy, 131, 132
anti-immunoglobulin E, 136, 137, 409, 410
basic concepts, 129, 130
beta-agonists
long-acting, 138, 13
short-acting, 137, 138
classification of treatments, 128
concomitant diseases, 140
corticosteroids
inhaled, 132–134
oral, 134, 135
cromolyn sodium, 135, 136
goals, 128, 129
inhaled, 131, 132
ipratropium bromide, 140
leukotriene modifiers, 136
nedocromil sodium, 135, 136
theophylline, 139, 356, 357
occupational asthma, 114, 115
pathophysiology
airway inflammation, 121, 122
bronchial hyperresponsiveness, 122
bronchial smooth muscle contraction, 121
epithelial desquamation, 122, 123
mucosal edema, 121
mucus secretion, 122
overview, 120, 121
predisposing factors
autonomic dysfunction, 124
genetics, 123
vasculitis, 117
Adverse drug reactions, see Drug adverse reactions
Air filtration, devices, 427, 428
Albuterol
anaphylaxis management, 70
childhood asthma management, 91, 93
Allergen immunotherapy, see also Venom immunotherapy
adverse reactions
anaphylaxis, 61
local adverse reactions, 439, 440
systemic reactions, 440
treatment medications and equipment, 441, 442
allergen sources, 430, 431
allergen vaccines, 431
allergic rhinitis management, 432–435
asthma management
adult asthma, 131, 132
animal dander, 438
dust mite, 438
mold, 438
overview, 435, 436
pollen, 436, 437
atopic dermatitis management, 244
duration, 439
failure causes, 439, 439
food allergy management, 292
immunological changes in successful therapy, 432
indications, 430, 431
ocular allergy management, 196
patient selection, 439
precautions, 440, 441
prospects, 442, 443
Allergens
atopic dermatitis
aeroallergens, 220, 221
foods, 221–223
microorganisms, 223–225
food allergens and antigens, 276, 277
protein contact dermatitis, 267
Allergic asthma, see Adult asthma
Allergic bronchopulmonary aspergillosis (ABPA), features, 112, 113
Allergic conjunctivitis, see Ocular allergy

Allergic rhinitis
  classification, 149, 150
  differential diagnosis
    allergic rhinitis, 150–152
    atrophic rhinitis, 155, 156
    nonallergic rhinitis with eosinophilia, 153, 154
    perennial nonallergic rhinitis, 152, 163
    rhinitis, 144, 145
    rhinitis medicamentosa, 154, 155
    systemic diseases or anatomical defects, 156, 157
  epidemiology, 147, 149
  management
    allergen avoidance, 158, 160
    allergen immunotherapy, 158, 160, 161
    overview, 157, 158
    pharmacotherapy
      antihistamines, 332
cromolyn sodium, 373
oral, 162–164
topical, 161, 162
prospects, 164
stepwise approach, 159
  pathophysiology, 144, 146, 147

Allergy, unconventional theories, 446, 447

ALPSk, see Autoimmune lymphoproliferative syndrome

Anaphylaxis
  causes
    allergen immunotherapy, 61
    exercise, 61, 62
    foods, 59, 60
    hemodialysis, 62
    idiopathic anaphylaxis, 63
    insect bites and stings, 60
    insulin, 62
    latex, 61
    local anesthetics, 63
    medications, 57, 58
    overview, 52
    plasma exchange, 62
    radiocontrast media, 62, 63
  clinical manifestations, 55, 56
  differential diagnosis, 63–66
  food allergy, 279–281
  history of study, 51, 52
  management, 68–70
  pathophysiology, 52–55
  prevention, 66–68
  risk factors, 56, 57

Anesthesics, adverse reactions
  anaphylaxis induction by local anesthetics, 63
  mechanisms, 305
  diagnosis and management, 314, 315

Angioedema
  classification and etiology, 201–205
  clinical presentation, 199, 200
  evaluation and workup, 206–208
  management, 211–214
  pathophysiology, 208–210
  physical stimuli, 204, 205
  thermal stimuli, 205

Angiotensin-converting enzyme (ACE) inhibitors
  adverse reactions
    diagnosis, 317
    management, 317
    mechanisms, 304
  angioedema induction, 203
  avoidance in anaphylaxis, 67

Angiotensin receptor blockers, adverse reactions
  diagnosis and management, 317
  mechanisms, 304

Animal dander
  allergen immunotherapy, 435, 438
  bird, 48
  cat, 47, 48, 423, 424
dog, 48, 424
environmental control, 423, 424, 425
furred pests, 48
overview, 47
rodent, 425

Antibiotic therapy
  adverse reactions
    diagnosis and management
      β-lactam antibiotics, 310–312
      sulfonamides, 312–314
    mechanisms
      ciprofloxin, 303
      β-lactam antibiotics, 299–301
      sulfonamides, 303
      vancomycin, 303
  atopic dermatitis management, 243
  otitis media, 177–179
  sinusitis, 172, 173

Antihistamines
  allergic rhinitis management, 162, 163
  anaphylaxis management, 70
  atopic dermatitis management, 242
  atopy development prevention in children, 333
  drug adverse reaction management, 308
  first-generation drugs
    pharmacodynamics, 324, 326
    pharmacokinetics, 323, 326
    side effects, 327
  second-generation drugs
    anti-allergic effects of H1-antagonists, 331
    definition, 327, 328
    pharmacodynamics, 330
    pharmacokinetics, 328–330
    side effects, 331, 332
  urticaria and angioedema management, 212, 213

Anti-immunoglobulin E, see Omalizumab

ARA, see Autosomal recessive agammaglobulinemia

Aspartame, intolerance reactions, 284

Aspirin
  adult asthma precipitation, 115, 116
  adverse reactions
    diagnosis and management, 316
    mechanisms, 303

Asthma, see Adult asthma; Childhood asthma

AT, see Ataxia telangiectasia

Ataxia telangiectasia (AT), features, 461, 462
Atopic dermatitis (AD)
- allergens
  - aeroallergens, 220, 221
  - foods, 221–223
  - microorganisms, 223–225
- complications
  - infection, 238, 239
  - ocular conditions, 239
  - skin conditions, 239, 240
- course, 218, 219
- diagnosis
  - history, 228
  - laboratory findings
    - hematological findings, 230
    - radioallergosorbent test, 231
    - serum immunoglobulin E, 230
    - skin testing, 230, 231
  - physical examination, 228, 229
- differential diagnosis
  - immunological diseases, 237, 238
  - metabolic disorders, 237
  - skin diseases, 236, 237
- environmental factors
  - climate, 225, 226
  - irritants, 226
  - occupation, 227
  - psychosocial factors, 226, 227
- food allergy, 281
- genetics, 227
- histopathology, 231–233
- history of study, 218
- immunopathology
  - immunoglobulin E, 233, 234
  - overview, 233
  - T-helper cells, 234–236
  - allergen immunotherapy, 244
  - antibiotic therapy, 243
  - antihistamines, 332
  - antipruritics, 242
  - coal tar preparations, 243
  - complementary and alternative medicine, 245, 246
  - corticosteroids, 242, 243
  - cromolyn sodium, 374, 375
  - cyclosporine A, 245
  - dietary restriction, 241
  - environmental control, 240, 241
  - interferon-γ, 244, 245
  - phototherapy, 244
  - psychotherapy, 246
  - skin care, 241, 242
  - tacrolimus, 245
- prevalence, 218
- prognosis, 246, 247
- Atopic keratoconjunctivitis, see Ocular allergy
- Atrophic rhinitis, features, 155, 156
- Atropine, 380
- respiratory disease indications, 381, 382
- Audiometry, otitis media diagnosis, 176
- Autoimmune lymphoproliferative syndrome (ALPS), features, 463, 464
- Autosomal recessive agammaglobulinemia (ARA), features, 458
- Azelastine
  - allergic rhinitis management, 162
  - ocular allergy management, 195
- Bacterial conjunctivitis, see Ocular allergy
- Basophil
  - allergic response mediators, 6–9
  - cytokines, 8, 9
  - immunoglobulin E in sensitization, 405, 406
  - target organ effects of mediators, 11, 12
- Bee, see Insect bites and stings
- Beta-agonists
  - administration routes, 340
  - adrenergic receptor classes, 336
  - adult asthma management
    - long-acting, 138, 139
    - short-acting, 137, 138
  - adverse effects, 340, 341
  - childhood asthma management
    - long-acting, 91, 92
    - short-acting, 93
  - Olympics drug rules, 341, 342
  - types
    - first-generation, 336
    - fourth-generation, 339
    - second-generation, 336, 338
    - structures, 337
    - third-generation, 338, 339
- Beta-blockers, adult asthma precipitation, 116
- Bioresonance information therapy (BIT), atopic dermatitis management, 246
- Bird, allergens, 48
- BIT, see Bioresonance information therapy
- Blepharconjunctivitis, see Ocular allergy
- Blood transfusion, adverse reactions, 303
- Bruton’s disease, features, 458
- Cat
  - allergens, 47, 48
  - environmental control, 423, 424
- Cataract, corticosteroid risks, 393, 394, 399, 400
- Celiac disease, atopic dermatitis differential diagnosis, 237
- CGD, see Chronic granulomatous disease
- CH50, complement deficiency screening, 471
- Chemical avoidance therapy, controversy, 449
- Chemotherapy agents, adverse reactions, 305
- Childhood asthma
  - diagnosis, 84–87
  - differential diagnosis, 87
  - epidemiology, 83, 84
  - exacerbations and management, 101–104
  - management
    - action plan, 100
    - care approaches, 94–99
    - environmental control, 87–90
    - pharmacotherapy
      - albuterol, 91, 93
      - anti-immunoglobulin E, 92
      - cromolyn sodium, 92
      - formeterol, 91, 92
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>inhaled corticosteroids, 90, 91, 94</td>
<td></td>
</tr>
<tr>
<td>ipratropium bromide, 93</td>
<td></td>
</tr>
<tr>
<td>leukotriene modifiers, 91</td>
<td></td>
</tr>
<tr>
<td>oral corticosteroids, 93</td>
<td></td>
</tr>
<tr>
<td>salmeterol, 91, 92</td>
<td></td>
</tr>
<tr>
<td>theophylline, 92, 93, 356, 357</td>
<td></td>
</tr>
<tr>
<td>pathogenesis, 84</td>
<td></td>
</tr>
<tr>
<td>patient education, 95</td>
<td></td>
</tr>
<tr>
<td>referral guidelines, 104</td>
<td></td>
</tr>
<tr>
<td>risk factors, 85, 86</td>
<td></td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease (COPD), ipratropium bromide, 382–384</td>
<td></td>
</tr>
<tr>
<td>Coal tar, atopic dermatitis management, 243</td>
<td></td>
</tr>
<tr>
<td>Cockroach</td>
<td></td>
</tr>
<tr>
<td>allergens, 49</td>
<td></td>
</tr>
<tr>
<td>environmental control, 521, 422</td>
<td></td>
</tr>
<tr>
<td>Common variable immunodeficiency (CVID), features, 460</td>
<td></td>
</tr>
<tr>
<td>Complement</td>
<td></td>
</tr>
<tr>
<td>activation in serum sickness, 309</td>
<td></td>
</tr>
<tr>
<td>anaphylaxis pathophysiology, 54, 55</td>
<td></td>
</tr>
<tr>
<td>deficiencies, 466, 471</td>
<td></td>
</tr>
<tr>
<td>Computed tomography (CT), sinusitis diagnosis, 170</td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis, see Ocular allergy</td>
<td></td>
</tr>
<tr>
<td>Contact dermatitis</td>
<td></td>
</tr>
<tr>
<td>allergic versus irritant contact dermatitis, 254, 255, 259</td>
<td></td>
</tr>
<tr>
<td>atopic dermatitis differential diagnosis, 237</td>
<td></td>
</tr>
<tr>
<td>definition, 249, 250</td>
<td></td>
</tr>
<tr>
<td>diagnosis, 250, 252, 253</td>
<td></td>
</tr>
<tr>
<td>differential diagnosis, 260</td>
<td></td>
</tr>
<tr>
<td>features by site</td>
<td></td>
</tr>
<tr>
<td>elbows and knees, 260</td>
<td></td>
</tr>
<tr>
<td>eyelids, 187, 188, 262, 263</td>
<td></td>
</tr>
<tr>
<td>face, 263</td>
<td></td>
</tr>
<tr>
<td>feet, 264</td>
<td></td>
</tr>
<tr>
<td>flexural areas, 259</td>
<td></td>
</tr>
<tr>
<td>hands, 255, 257–259</td>
<td></td>
</tr>
<tr>
<td>legs and thighs, 264</td>
<td></td>
</tr>
<tr>
<td>lips and perioral skin, 263</td>
<td></td>
</tr>
<tr>
<td>scalp, 260, 262</td>
<td></td>
</tr>
<tr>
<td>trunk, 263</td>
<td></td>
</tr>
<tr>
<td>latex allergy, 269, 270</td>
<td></td>
</tr>
<tr>
<td>management, 268, 269</td>
<td></td>
</tr>
<tr>
<td>protein contact dermatitis</td>
<td></td>
</tr>
<tr>
<td>allergens, 267</td>
<td></td>
</tr>
<tr>
<td>clinical features, 265, 266</td>
<td></td>
</tr>
<tr>
<td>patch testing, 266, 268</td>
<td></td>
</tr>
<tr>
<td>COPD, see Chronic obstructive pulmonary disease</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td></td>
</tr>
<tr>
<td>allergic rhinitis management</td>
<td></td>
</tr>
<tr>
<td>oral, 163, 164</td>
<td></td>
</tr>
<tr>
<td>topical, 161, 162</td>
<td></td>
</tr>
<tr>
<td>anaphylaxis prevention, 70</td>
<td></td>
</tr>
<tr>
<td>asthma management</td>
<td></td>
</tr>
<tr>
<td>inhaled corticosteroids</td>
<td></td>
</tr>
<tr>
<td>adult asthma, 132–134</td>
<td></td>
</tr>
<tr>
<td>adverse effects, 397–400</td>
<td></td>
</tr>
<tr>
<td>bronchial hyperresponsiveness effects, 388</td>
<td></td>
</tr>
<tr>
<td>children, 90, 91, 94</td>
<td></td>
</tr>
<tr>
<td>dosing guidelines, 397, 398</td>
<td></td>
</tr>
<tr>
<td>first-line therapy, 396</td>
<td></td>
</tr>
<tr>
<td>formulations, 396, 397</td>
<td></td>
</tr>
<tr>
<td>oral corticosteroids</td>
<td></td>
</tr>
<tr>
<td>adult asthma, 134, 135</td>
<td></td>
</tr>
<tr>
<td>adult exacerbations, 388, 389</td>
<td></td>
</tr>
<tr>
<td>bronchial hyperresponsiveness effects, 388</td>
<td></td>
</tr>
<tr>
<td>children, 93, 389, 390</td>
<td></td>
</tr>
<tr>
<td>chronic severe asthma, 390, 391</td>
<td></td>
</tr>
<tr>
<td>atopic dermatitis management, 242, 243</td>
<td></td>
</tr>
<tr>
<td>chemistry, 386</td>
<td></td>
</tr>
<tr>
<td>drug adverse reaction management, 308</td>
<td></td>
</tr>
<tr>
<td>ocular allergy management</td>
<td></td>
</tr>
<tr>
<td>sinusitis management, 173, 174</td>
<td></td>
</tr>
<tr>
<td>urticaria and angioedema management, 212–214</td>
<td></td>
</tr>
<tr>
<td>systemic therapy</td>
<td></td>
</tr>
<tr>
<td>adverse effects, 391–395</td>
<td></td>
</tr>
<tr>
<td>pharmacokinetics, 386–388</td>
<td></td>
</tr>
<tr>
<td>Cromoly sodium</td>
<td></td>
</tr>
<tr>
<td>allergic rhinitis management</td>
<td></td>
</tr>
<tr>
<td>asthma management</td>
<td></td>
</tr>
<tr>
<td>adults, 135, 136</td>
<td></td>
</tr>
<tr>
<td>children, 92</td>
<td></td>
</tr>
<tr>
<td>efficacy, 369–373</td>
<td></td>
</tr>
<tr>
<td>atopic dermatitis management, 374, 375</td>
<td></td>
</tr>
<tr>
<td>history of use, 368</td>
<td></td>
</tr>
<tr>
<td>mastocytosis management</td>
<td></td>
</tr>
<tr>
<td>mechanisms of action, 369</td>
<td></td>
</tr>
<tr>
<td>ocular allergy management</td>
<td></td>
</tr>
<tr>
<td>atopic keratoconjunctivitis</td>
<td></td>
</tr>
<tr>
<td>giant papillary conjunctivitis, 374</td>
<td></td>
</tr>
<tr>
<td>seasonal allergic conjunctivitis, 373, 374</td>
<td></td>
</tr>
<tr>
<td>vernal keratoconjunctivitis</td>
<td></td>
</tr>
<tr>
<td>safety, 375, 376</td>
<td></td>
</tr>
<tr>
<td>structure, 368</td>
<td></td>
</tr>
<tr>
<td>CT, see Computed tomography</td>
<td></td>
</tr>
<tr>
<td>CVID, see Common variable immunodeficiency</td>
<td></td>
</tr>
<tr>
<td>Cyclic neutropenia, features, 464, 465</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine A</td>
<td></td>
</tr>
<tr>
<td>atopic dermatitis management, 245</td>
<td></td>
</tr>
<tr>
<td>ocular allergy management</td>
<td></td>
</tr>
<tr>
<td>DBPCFC, see Double-blind, placebo-controlled food challenge</td>
<td></td>
</tr>
<tr>
<td>Degranulation, mechanism, 2, 3</td>
<td></td>
</tr>
<tr>
<td>Diagnosis, allergy</td>
<td></td>
</tr>
<tr>
<td>controversial techniques, 447–449</td>
<td></td>
</tr>
<tr>
<td>criteria, 28</td>
<td></td>
</tr>
<tr>
<td>history, 16–20, 29</td>
<td></td>
</tr>
<tr>
<td>immunoglobulin E level</td>
<td></td>
</tr>
<tr>
<td>allergen-specific antibody, 32–34</td>
<td></td>
</tr>
<tr>
<td>overview, 24, 27</td>
<td></td>
</tr>
<tr>
<td>total serum antibody, 34–36</td>
<td></td>
</tr>
<tr>
<td>physical examination, 20, 21, 29</td>
<td></td>
</tr>
<tr>
<td>prospects for testing, 36</td>
<td></td>
</tr>
<tr>
<td>skin testing</td>
<td></td>
</tr>
<tr>
<td>allergens for testing, 23</td>
<td></td>
</tr>
<tr>
<td>contraindications, 29, 30</td>
<td></td>
</tr>
<tr>
<td>controls, 31</td>
<td></td>
</tr>
<tr>
<td>epicutaneous tests, 30, 32</td>
<td></td>
</tr>
<tr>
<td>gold standard, 22</td>
<td></td>
</tr>
</tbody>
</table>
intradermal tests, 30–32
physiology, 28, 29
quality control, 31, 32
recording and scoring, 31

Dietary supplements, controversies, 450

Differential diagnosis
anaphylaxis, 63–66
asthma
adults, 119, 120
children, 87
contact dermatitis, see Contact dermatitis
ocular allergy, 183
rhinitis
allergic rhinitis, 150–152
atrophic rhinitis, 155, 156
nonallergic rhinitis with eosinophilia, 153, 154
overview, 144, 145
perennial nonallergic rhinitis, 152, 163
rhinitis medicamentosa, 154, 155
systemic diseases or anatomical defects, 156, 157

DiGeorge syndrome
atopic dermatitis differential diagnosis, 237
features, 461

Diphenhydramine, anaphylaxis management, 70

Dog
allergens, 48
environmental control, 424

Double-blind, placebo-controlled food challenge (DBPCFC), food allergy and intolerance diagnosis, 272, 276, 281, 285, 288, 289

Doxepin, atopic dermatitis management, 242

Drug adverse reactions
anaphylaxis, 57, 58
classification, 296, 297
clinical presentation
generalized reaction, 305, 306
organ-specific reactions, 307
skin reactions, 306, 307
definitions, 296
diagnosis and management by type
anesthetics, 314, 315
angiotensin receptor blockers, 317
angiotensin-converting enzyme inhibitors, 317
aspirin, 316
insulin, 314
β-lactam antibiotics, 310–312
nonsteroidal anti-inflammatory drugs, 316
radiocontrast media, 316
sulfonamides, 312–314
incidence and factors affecting, 297–299
management
antihistamines, 308
corticosteroids, 308
follow-up, 310
general approach, 307, 308
graded drug challenge, 309
skin testing, 309
mechanisms
anesthetics, 305
angiotensin receptor blockers, 304
angiotensin-converting enzyme inhibitors, 304
aspirin, 303
blood transfusion, 303
chemotherapy agents, 305
ciprofloxin, 303
heterologous serum, 302
insulin, 301
β-lactam antibiotics, 299–301
monoclonal antibodies, 303
nonsteroidal anti-inflammatory drugs, 303, 304
opiates, 305
protamine, 302
radiocontrast media, 304
sulfonamides, 303
vaccines, 302
vancomycin, 303

Duncan disease, features, 463
Dust, allergens, 45

Dust mite
caudal immunotherapy, 435, 438
allergens, 46, 47
environmental control, 418–421

Early-phase response, pathophysiology, 12, 13

Ectodermal dysplasia, features, 45

Emedastine, ocular allergy management, 195

Environmental allergens
control, see Environmental control
exposure classification, 40
indoor allergens, 45–49
outdoor allergens, 40–45
overview, 39, 40

Environmental control
air filtering devices, 427, 428
animal dander
cat, 423, 424
dog, 424
rodent, 425
asthma management, 87–90
atopic dermatitis management, 240, 241
benefits, 417, 418
cockroach, 521, 422
dust mite, 418–421
fungi, 426, 427
overview, 428

Epinephrine, anaphylaxis management, 68–70, 291

Exercise
anaphylaxis induction, 61, 62
asthma induction, 127, 128

Exfoliative dermatitis, differential diagnosis, 265

Eye, see Ocular allergy

Fluorescein staining, eye, 193
Flush, differential diagnosis, 63–66

Food allergy
anaphylaxis, 59, 60, 279–281
atopic dermatitis, 281
causitive foods and additives, 275
definition, 271, 272
diagnosis
double-blind, placebo-controlled food challenge, 272, 276, 281, 285, 288, 289
food diary, 288
history, 285, 286
skin testing, 286–288
Food avoidance therapy, controversy, 449
Food intolerance
additive intolerance reactions, 278, 279, 283–285
definition, 271, 272
diagnosis
double-blind, placebo-controlled food challenge, 272, 276, 281, 285, 288, 289
food diary, 288
history, 285, 286
skin testing, 286–288
frequency, 272, 273
gastrointestinal reactions, 281–283
management
allergen-free diet, 288
allergen immunotherapy, 292
emergencies, 290, 291
food rechallenge, 292
infant formula resubstitution, 292, 293
overview, 290
natural history of clinical reactions, 273, 274
pathophysiology, 274–276
protein allergens and antigens, 276, 277
pulmonary reactions, 283
Formeterol
childhood asthma management, 91, 92
mechanism of action, 339
Fungi
allergen immunotherapy, 435, 438
environmental control, 426, 427
indoor allergens, 46
outdoor allergens, 44, 45
Gastroesophageal reflux disease (GERD), asthma exacerbation, 118
General anesthetics, see Anesthetics
GERD, see Gastroesophageal reflux disease
Giant papillary conjunctivitis, see Ocular allergy, 188, 189
Glaucoma, corticosteroid risks, 399, 400
Glucocorticoids, see Corticosteroids
Glucose-6-phosphate dehydrogenase, deficiency, 465, 471
Grass, pollen, 43
Growth suppression, corticosteroid risks, 394, 397–399
Hemodialysis, anaphylaxis induction, 62
Herbal therapy
atopic dermatitis management, 245
controversies, 450, 451
Histamine
anaphylaxis pathophysiology, 52, 53
immune regulation, 322
receptors and activation effects, 52, 319–322
synthesis, 6, 7, 139
Histamine-releasing factors (HRFs), urticaria and
angioedema pathophysiology, 208–210
Histidine, food content, 278
History
allergy evaluation, 16–20, 29
atopic dermatitis, 228
food allergy and intolerance diagnosis, 285, 286
immunodeficiency disorders, 455
HIV, see Human immunodeficiency virus
Hives, see Urticaria
HRFs, see Histamine-releasing factors
Human immunodeficiency virus (HIV), management, 472
Hydroxyzine, atopic dermatitis management, 242
Hyperimmunoglobulin E syndrome, atopic dermatitis
differential diagnosis, 238
Hyperimmunoglobulin M syndrome, features, 459
IgE, see Immunoglobulin E
Immunodeficiency
clinical presentation in children, 454, 455
disorders
antibody disorders, 458–461
complement defects, 466
diagnostic tests, 466–471
phagocytic defects, 464–466
primary disorders, 455–458
secondary disorders, 458
T-cell and combined disorders, 461–464
treatment, 472
family history, 455
Immunoglobulin A deficiency, atopic dermatitis
differential diagnosis, 238
Immunoglobulin E (IgE)
allergic rhinitis pathophysiology, 144, 146, 147
allergic-like reactions, 277, 278
anti-immunoglobulin E, see Omalizumab
atopic dermatitis
diagnosis, 230
pathophysiology, 233, 234
basophil and mast cell sensitization, 405, 406
class switching, 4, 5
developmental expression, 6
diagnostic measurement
allergen-specific antibody, 32–34
overview, 24, 27
total serum antibody, 34–36
food allergy pathophysiology, 274–276
functions, 410, 411
receptors, 3
therapeutic targeting rationale, 405, 406
Immunoglobulin G autoantibody, urticaria and
angioedema pathophysiology, 210, 214
Immunotherapy, see Allergen immunotherapy
Infant formula, resubstitution in allergy, 292, 293
Inhaler
metered dosing, 131, 132
technique, 132, 133
Insect bites and stings
allergy tests, 75
anaphylaxis management and prophylaxis, 75, 76
sting reactions
  anaphylaxis, 60, 72–74
  large local reactions, 73
  normal reaction, 73
  toxic reactions, 74
  unusual reactions, 74
stinging insect types, 72, 73
venom immunotherapy
  dosing schedule, 77, 78
  efficacy, 80
  monitoring, 79, 80
  patient selection, 76
  pregnancy safety, 79
  reactions, 78, 79
  termination, 80, 81
  venom selection, 76, 77
Insulin
  adverse reactions
    diagnosis and management, 314
    mechanisms, 301
    anaphylaxis induction, 62
Interferon-γ
  atopic dermatitis management, 244, 245
  receptor deficiency, 465, 466
Intravenous immunoglobulin (IVIG), immunodeficiency management, 472
Ipratropium bromide
  allergic rhinitis management, 162
  asthma management
    adults, 140
    bronchodilatory activity, 382–384
    children, 93
  chronic obstructive pulmonary disease management, 382–384
  parasympathetic nervous system
    asthma role, 381
    control of airways, 380, 381
    structure, 380
IVIG, see Intravenous immunoglobulin
Keratoconjunctivitis sicca, see Ocular allergy
Kostmann syndrome, features, 464
Lactose intolerance, features, 278, 282, 284
LAD, see Leukocyte adhesion deficiency
Langerhans cell histiocytosis, atopic dermatitis differential diagnosis, 238
Late-phase response, pathophysiology, 12, 13
Latex
  anaphylaxis induction, 61
  hand eruptions in health care workers, 269, 270
Leiner’s disease, atopic dermatitis differential diagnosis, 238
Leukocyte adhesion deficiency (LAD), features, 465
Leukotriene receptor antagonists
  asthma management
    adults, 136
    children, 91, 101
    chronic asthma studies, 363, 364
    recommendations, 364, 365
    safety, 364
Leukotrienes
  allergic response, 7
  anaphylaxis pathophysiology, 53
  biosynthesis and potency, 362, 363
  Levocabastine, ocular allergy management, 194
  Local anesthetics, see Anesthetics
Magnetic resonance imaging (MRI), sinusitis diagnosis, 170, 171
MAOIs, see Monoamine oxidase inhibitors
Mast cell
  activation, 9–12
  adult asthma role, 109, 110
  allergic response mediators, 6–9
  cytokines, 8, 9
  immunoglobulin E in sensitization, 405, 406
  production, 6
  tryptase, 289
  types, 6
Mastocytosis, cromolyn sodium management, 375
Milk allergy, infant formula resubstitution, 292, 293
Mold, see Fungi
Mold, spores, 46
Monoamine oxidase inhibitors (MAOIs), food precaution, 278
Monoclonal antibodies
  adverse reactions, 303
  anti-immunoglobulin E, see Omalizumab
Monosodium glutamate (MSG), reactions, 63, 64, 278, 284
Montelukast
  allergic rhinitis management, 163
  safety, 364
MPO, see Myeloperoxidase
MRI, see Magnetic resonance imaging
MSG, see Monosodium glutamate
Myeloperoxidase (MPO), deficiency, 465, 471
Myopathy, corticosteroid risks, 392, 393
NARES, see Nonallergic rhinitis with eosinophilia
NBS, see Nijmegen breakage syndrome
Nedocromil sodium
  allergic rhinitis management, 373
  asthma management
    adults, 135, 136
    efficacy, 369–373
  atopic dermatitis management, 374, 375
  history of use, 368
  mastocytosis management, 375
  mechanisms of action, 369
  ocular allergy management
    atopic keratoconjunctivitis, 374
    giant papillary conjunctivitis, 374
    seasonal allergic conjunctivitis, 373, 374
    vernal keratoconjunctivitis, 374
    safety, 375, 376
    structure, 368
NEMO, see Nuclear factor--κB essential modulator
Neutral proteases, allergic response, 7
Neutralization therapy, controversy, 449
Nijmegen breakage syndrome (NBS), features, 462
Nitric oxide (NO), anaphylaxis pathophysiology, 54
NO, see Nitric oxide
Nonallergic rhinitis with eosinophilia (NARES), features, 153, 154
Nonsteroidal anti-inflammatory drugs (NSAIDs)
adult asthma precipitation, 115, 116
adverse reactions
diagnosis and management, 316
mechanisms, 303, 304
urticaria and angioedema induction, 202
NSAIDs, see Nonsteroidal anti-inflammatory drugs
Nuclear factor-κB essential modulator (NEMO),
deficiency, 459, 460
Nummular eczema, atopic dermatitis differential
diagnosis, 236
Occupational asthma, features, 114, 115
Ocular allergy
clinical presentation
allergic conjunctivitis, 185
atopic keratoconjunctivitis, 186, 187
bacterial conjunctivitis, 189, 190
blepharoconjunctivitis, 187
contact dermatitis of eyelids, 187, 188
giant papillary conjunctivitis, 188, 189
keratoconjunctivitis sicca, 191
physical examination, 184, 185
proposis, 191
vernal conjunctivitis, 185, 186
viral conjunctivitis, 190, 191
differential diagnosis, 183
disease types, 182
management
allergen avoidance, 194
allergen immunotherapy, 196
antihistamines, 194, 195
corticosteroids, 195
cromolyn sodium
atopic keratoconjunctivitis, 374
giant papillary conjunctivitis, 374
overview, 195
seasonal allergic conjunctivitis, 373, 374
vernal keratoconjunctivitis, 374
cyclosporin A, 196
drug formulations, 193
epinastine, 195
olopatadine, 195
overview, 197
pemirolast potassium, 195
prospects, 196
ocular examination, 192
ocular surface, 182
ophthalmic procedures and testing, 192, 193
overview, 181, 182
Ocular provocation testing, allergy diagnosis, 193
Omalizumab
allergic rhinitis management, 162
ocular allergy management, 195
adverse events, 409
asthma management
adults, 136, 137, 409, 410
children, 92, 411, 412
patient selection, 410
chemistry, 404
clinical trials, 408
diagnostic test interference, 410
duration of therapy, 407
efficacy, 408
long-term effects, 408
mechanism of action
binding properties, 406
direct pharmacological effects, 406, 407
overview, 403, 404
receptor downregulation, 407
pharmacodynamics, 404, 405
pharmacokinetics and metabolism, 405
potential indications
allergen immunotherapy combination, 412, 413
allergic rhinitis, 412
children, 411, 412
food allergy, 412
prospects, 413
quality of life outcomes, 409
specificity, 407
Opiates, adverse reactions, 305
Osteoporosis, adverse reactions, 391, 392, 399
Otitis media
classification
clinical presentation
acute otitis media, 175
otitis media with effusion, 176
diagnosis, 176
epidemiology, 175
medical therapy
acute otitis media, 177
otitis media with effusion, 179
recurrent disease, 177, 179
microbiology, 176
pathogenesis, 175
recurrent or persistent disease evaluation, 179
surgical therapy, 179
PAF, see Platelet-activating factor
Parasympathetic nervous system
asthma role, 381
control of airways, 380, 381
Patch testing, protein contact dermatitis, 266, 268
Peak flow monitoring, childhood asthma, 101
Peanut allergy, anaphylaxis induction, 59, 60
Pemirolast potassium, ocular allergy management, 195
Perennial nonallergic rhinitis (PNAR), features, 152, 163
PGI2, see Prostacyclin
Phenylketonuria, atopic dermatitis differential diagnosis, 237
Phototherapy, atopic dermatitis management, 244
Physical examination
adult asthma, 125, 126
allergy evaluation, 20, 21, 29
atopic dermatitis, 228, 229
ocular allergy, 184, 185, 192
Plasma exchange, anaphylaxis induction, 62
Platelet-activating factor (PAF), allergic response, 8
PNAR, see Perennial nonallergic rhinitis
PNP, see Purine nucleoside phosphorylase
Pollen
allergen immunotherapy, 435–437
distribution, 42
Index

grass, 43
morphology, 41, 42
seasons, 42
species, 44
tree, 42, 43
weed, 43
Pregnancy, asthma exacerbation, 119
Prevalence, allergy, 15
Probiotics
  atopic dermatitis management, 246
  food allergy prevention in children, 293
Proptosis, see Ocular allergy
Prostacyclin (PGI2), synthesis, 8
Protamine, adverse reactions, 302
Protein contact dermatitis, see Contact dermatitis
Psoriasis, atopic dermatitis differential diagnosis, 237
Psychotherapy, atopic dermatitis management, 246
Purine nucleoside phosphorylase (PNP), deficiency, 463
Radioallergosorbent test (RAST)
  atopic dermatitis diagnosis, 231
  venom testing, 75
Radiocontrast media (RCM)
  adverse reactions
    anaphylaxis, 62, 63
    diagnosis and management, 316
    mechanisms, 304
  mast cell degranulation, 201
RAG genes, deficiency, 463
Ranitidine, anaphylaxis management, 70
RAS, see Radioallergosorbent test
RCM, see Radiocontrast media
Respiratory syncytial virus (RSV), adult asthma, 114
Rhinitis, see Allergic rhinitis
Rhinitis medicamentosa, features, 154, 155
RSV, see Respiratory syncytial virus
Salmeterol
  childhood asthma management, 91, 92
  mechanism of action, 339
Saurine, reactions, 64
Schirmer’s tear test, ocular allergy, 192
SCID, see Severe combined immune deficiency
Seborrheic dermatitis, atopic dermatitis differential diagnosis, 236
Selective immunoglobulin A deficiency (SIGAD), features, 460
Sensitization, mechanism, 2, 3
Severe combined immune deficiency (SCID)
  atopic dermatitis differential diagnosis, 237, 238
  features, 461, 469
SIGAD, see Selective immunoglobulin A deficiency
Sinusitis
  asthma exacerbation, 117, 118
  clinical presentation
    acute sinusitis, 168
    chronic sinusitis, 169
    symptoms, 170
  definition, 167
  diagnosis
    imaging, 170, 171
    laboratory tests, 170
    maxillary aspiration and culture, 171
epidemiology, 167
medical therapy
  acute sinusitis, 172, 173
  chronic sinusitis, 173, 174
microbiology
  acute sinusitis, 171
  chronic sinusitis, 171, 172
pathogenesis, 168
recurrent or persistent disease evaluation, 174
surgical therapy, 174
Skin testing
  allergens for testing, 23
  atopic dermatitis diagnosis, 230, 231
  contraindications, 29, 30
  controls, 31
  drug adverse reaction management, 309
  epicutaneous tests, 30, 32
  food allergy and intolerance diagnosis, 286–288
  gold standard, 22
  intradermal tests, 30–32
  physiology, 28, 29
  quality control, 31, 32
  recording and scoring, 31
Spirometry, childhood asthma diagnosis, 85, 86
Sting, see Insect bites and stings
Sulfite, intolerance reactions, 278, 279, 284
Sulfur dioxide, adult asthma precipitation, 116
Tacrolimus, atopic dermatitis management, 245
Th2, see T-helper 2 cell
T-helper 2 cell (TH2)
  allergic inflammation role, 12
  atopic dermatitis pathophysiology, 234–236
  cytokines and immunoglobulin E class switching, 5
Theophylline
  asthma management
    adult asthma, 139
    childhood asthma, 92, 93
    dose titration, 356, 357
    intravenous dosing, 354, 355
    recommendations, 355–358
    history of use, 343, 344
    mechanism of action
      adenosine receptor antagonism, 345
      phosphodiesterase inhibition, 344, 345
    pharmacodynamics, 351
    pharmacokinetics
      absorption
        rapid-release formulations, 346
        slow-release formulations, 346
      distribution, 347
      metabolism and elimination, 347–349
      therapeutic monitoring, 349–351
      toxicity, 351–354
THI, see Transient hypogammaglobulinemia
Thomboxane A2
  anaphylaxis pathophysiology, 53
  synthesis, 8
Tiotropium bromide
  bronchodilatory activity in asthma, 382–384
  chronic obstructive pulmonary disease management, 382–384
  Transient hypogammaglobulinemia (THI), features, 461
Tree, pollen, 42, 43
Tympanocentesis, otitis media diagnosis, 176
Tympanometry, otitis media diagnosis, 176

Urticaria
- acute urticaria, 201
- chronic urticaria, 201, 202
- classification and etiology, 201–205
- clinical presentation, 199, 200
- evaluation and workup, 206–208
- management, 211–214, 332
- pathophysiology, 208–210
- physical stimuli, 204, 205
- thermal stimuli, 205
- thyroid dysfunction, 213

Vaccines
- adverse reactions, 302
- allergens, see Allergen immunotherapy

Vasculitis, adult asthma, 117

Venom immunotherapy (VIT), see also Insect bites and stings
- dosing schedule, 77, 78
- efficacy, 80
- monitoring, 79, 80
- patient selection, 76

Vitamins
- pregnancy safety, 79
- reactions
  - fatigue and malaise, 79
  - local reactions, 79
  - systemic allergic reactions, 78, 79
  - termination, 80, 81
  - venom selection, 76, 77

Venom immunotherapy, see also Insect bites and stings
- XLA, see X-linked agammaglobulinemia
- X-linked agammaglobulinemia (XLA), features, 458
- X-linked lymphoproliferative syndrome (XLP), features, 463
- XLP, see X-linked agammaglobulinemia

Vernon, pollen, 43

Vernal conjunctivitis, see Ocular allergy

Viral conjunctivitis, see Ocular allergy

VIT, see Venom immunotherapy

Weed, pollen, 43

Wiskott-Aldrich syndrome
- atopic dermatitis differential diagnosis, 237
- features, 461

XLA, see X-linked agammaglobulinemia

Yellow jacket, see Insect bites and stings

Zafirlukast, safety, 364

ZAP-70, deficiency, 462